Time filter

Source Type

Ymittos Athens, Greece

Mourtzikou A.,National and Kapodistrian University of Athens | Kosmas K.,Anti cancer Oncological Hospital St. Savvas | Marouga A.,National and Kapodistrian University of Athens | Stamouli M.,Naval and Veterans Hospital | And 2 more authors.
Clinical Laboratory | Year: 2012

Backgound: Endometrial adenocarcinoma is the most common gynecologic malignancy and is the fifth most frequently diagnosed cancer in women. The objective of the present study was to determine the expression of a proliferation marker, Ki-67 and an apoptosis inhibitor, Bcl-2, by double-label staining in endometrial adenocarcinomas and in normal endometrium samples, to evaluate the differences in the immunocytochemical expression of Ki-67 and Bcl-2, and finally to correlate the results with tumor grade and stage. Methods: This study was carried on 270 endometrial samples, collected during a 27 month period, freshly resected from women who underwent total abdominal hysterectomy. Results: Ki-67 and Bcl-2 expressions were studied by immunocytochemistry. Bcl-2 expression was strong and homogeneous in normal (proliferative, secretory and atrophic) endometrium and more frequent in low-grade endometrioid carcinomas. Completely negative staining of Bcl-2 was found to be strictly related to high-grade endometrioid carcinomas. Ki-67 expression was higher in patients with high-grade endometrioid carcinomas. Proliferative endometrium showed inconclusive Ki-67 expression levels and in the secretory endometrium Ki-67 positive cells were remarkably diminished and even disappeared. Completely negative staining of Ki-67 was found to be strictly related to atrophic endometrium. Conclusions: Immunocytochemical double-label staining can be used to display the distribution of Bcl-2 and Ki-67 cells in endometrioid carcinomas as well as normal endometrium, and, in addition to cytomorphologic features, contributes to its accurate diagnosis.

Mourtzikou A.,National and Kapodistrian University of Athens | Stamouli M.,Naval and Veterans Hospital | Kroupis C.,National and Kapodistrian University of Athens | Christodoulou S.,National and Kapodistrian University of Athens | And 5 more authors.
Clinical Laboratory | Year: 2012

Background: Colorectal cancer (CRC) is a major public health problem and one of the leading causes of death worldwide. The aim of our study was: a) to determine the CEA, CA 19-9, EGFR, and EpCAM (GA733-2) levels both in healthy volunteers and in colorectal cancer patients, b) to evaluate the ELISA method for EGFR and EpCAM (GA733-2) measurement, and c) to correlate the tumor marker levels with clinicopathological findings in the CRC patients group. Methods: Our study was conducted on 50 blood samples obtained from CRC patients and 40 blood samples from healthy individuals. CEA and CA 19-9 measurements were performed using electrochemiluminescence immuneassay technology, while EGFR and EpCAM (GA733-2) measurements were performed by an in-house enzyme immunoassay. Results: CEA, CA 19-9, and EpCAM (GA733-2) levels were higher in the CRC patients group than in the control group. EGFR levels were lower in the patients group than in the control group. The mean levels of CA 19-9 and EpCAM (GA733-2) vary at different colon cancer stages. CEA, CA19-9, and EpCAM (GA733-2) vary according to performance status. Conclusions: CEA, CA 19-9, and EpCAM (GA733-2) showed similar specificity (80%, 80% and 84%, respectively). EGFR showed the lowest sensitivity and specificity. CA 19-9 was the marker with the highest sensitivity. The need for convenient tumour marker tests with high sensitivity is of great importance for early diagnosis and monitoring of CRC.

Damaskos C.,National and Kapodistrian University of Athens | Karatzas T.,National and Kapodistrian University of Athens | Nikolidakis L.,Ygeias Melathron Hospital | Kostakis I.D.,National and Kapodistrian University of Athens | And 5 more authors.
Anticancer Research | Year: 2015

Pancreatic carcinoma is one of the leading causes of cancer death. Current standard treatments include surgical resection, chemotherapy and radiotherapy but patient's prognosis remains poor and present severe side-effects. Contemporary oncology found a wide variety of novel anticancer drugs that regulate the epigenetic mechanisms of tumor genesis. Histone deacetylases (HDACs) are enzymes with pleiotropic activities that control critical functions of the cell through regulation of the acetylation states of histone proteins and other non-histone protein targets. They are divided into four groups, each with different localization in the cell, role and structure. Histone deacetylase inhibitors (HDACIs) are substances, which inhibit the function of HDACs. We recognize four leading groups (hydroxamic acid, cyclic tetrapeptide, benzamide, aliphatic acid). There are many HDACIs currently in pre-clinical and two (vorinostat, romidepsin) in clinical stages of investigation for pancreatic cancer. Numerous studies argue for the use HDACIs as monotherapy, others suggest that combination of HDACIs with other antitumor drugs has better therapeutic results. This review focuses on the use of HDACIs as novel anticancer drugs and will explain the mechanisms of therapeutic effect on pancreatic cancer. © 2015, International Institute of Anticancer Research. All rights reserved.

Dellis A.,Naval and Veterans Hospital | Boutsis D.,Naval and Veterans Hospital | Spyropoulos E.,Naval and Veterans Hospital | Galanakis I.,Naval and Veterans Hospital | And 2 more authors.
Nephro-Urology Monthly | Year: 2013

Testicular chloroma is an unusual form of extramedullary acute myeloid leukemia. We present a rare case that after chemotherapy relapsed with the appearance of metachronous testicular chloroma and we suggest prophylactic radiotherapy. © 2013, Nephrology and Urology Research Center.

Dellis A.,National and Kapodistrian University of Athens | Deliveliotis C.,Urologic | Kalentzos V.,Naval and Veterans Hospital | Vavasis P.,Naval and Veterans Hospital | Skolarikos A.,Urologic
International Braz J Urol | Year: 2014

Purpose: To examine the safety and efficacy of hyperbaric oxygen as the primary treatment for Grade IV radiation-induced haemorrhagic cystitis. Materials and Methods: Hyperbaric oxygen was prospectively applied as a primary treatment option in 11 patients with Grade IV radiation cystitis. Primary endpoint was the incidence of complete and partial response to treatment. Secondary endpoints included the duration of response, the correlation of treatment success-rate to the interval between the onset of haematuria and initiation of therapy, blood transfusion need and total radiation dose, the number of sessions to success, the avoidance of surgery and the overall survival. Results: All patients completed therapy without complications for a mean follow-up of 17.82 months (range 3 to 34). Mean number of sessions needed was 32.8 (range 27 to 44). Complete and partial response rate was 81.8% and 18.2%, respectively. However, in three patients the first treatment session was not either sufficient or durable giving a 72.7% rate of durable effect. Interestingly, all 9 patients with complete response received therapy within 6 months of the haematuria onset compared to the two patients with partial response who received therapy at 8 and 10 months from the haematuria onset, respectively (p = 0.018). The need for blood transfusion (p = 0.491) and the total radiation dose (p = 0.259) were not correlated to success-rate. One patient needed cystectomy, while all patients were alive at the end of follow-up. Conclusions: Early primary use of hyperbaric oxygen to treat radiation-induced grade IV cystitis is an effective and safe treatment option.

Discover hidden collaborations